Pfizer (PFE.US) and AbbVie (ABBV.US) Meet Rival! Eli Lilly (LLY.US) BTK Inhibitor Achieves Primary Endpoint in Phase III Clinical Trial
According to our financial news app, Pfizer (PFE.US) announced on Tuesday that its Bruton's tyrosine kinase (BTK) inhibitor, Jaypirca, has achieved the primary research endpoint in a phase III head-to-head clinical trial comparing Jaypirca with Imbruvica (ibrutinib) in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study directly compared the efficacy of Jaypirca and Imbruvica in untreated CLL/SLL patients. Based on the published top-line data, Jaypirca demonstrated a statistically significant advantage in overall response rate (ORR), achieving a non-inferiority primary endpoint regardless of whether it was used as first-line treatment or for patients who had previously received BTK inhibitor therapy.
Eli Lilly pointed out that while the data on progression-free survival (PFS) has not yet matured, it is already showing a trend favoring Jaypirca. The company said that further analysis will be conducted to verify the PFS advantage. In terms of safety, Jaypirca's performance was consistent with previous research results. The company plans to present detailed data at a medical conference later this year.
Currently, both Jaypirca and Imbruvica are oral targeted therapies approved by the US FDA for treating blood-based cancers such as CLL and SLL.